ClinicalTrials.gg
CompletedNCT00528957Updated Mar 14, 2018Results posted

Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children

A Phase 3 interventional study of Tenofovir DF and Zidovudine in HIV Infections, sponsored by Gilead Sciences. Completed at 9 sites in 3 countries. Open to participants aged 2 Years to 15 Years. Per ClinicalTrials.gov, last updated 2018-03-14.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
2 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 98 studies testing tenofovir in HIV Infections — 1 open to participants now, 3 under way, 1 of them phase 3. Tenofovir · HIV Infections.

Enrollment
48th of 94
97 · median 99
Started
2006
with 7 others
Phase 3
16 of 98
none open now
Registered
50th of 98
by date
Lead sponsor
17 of 98
Gilead Sciences

Among the 98 studies testing tenofovir in HIV Infections, this one is the 48th largest by enrollment of the 94 interventional ones that give a count, is one of 8 that started in 2006, is one of 16 in phase 3, and was the 50th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 98 studies testing tenofovir in HIV Infections is open now. Recruiting first, the newest first:

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 2 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing tenofovir in HIV Infections, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the efficacy of switching to tenofovir disoproxil fumarate (TDF) compared to continuing stavudine or zidovudine in maintaining virologic suppression in HIV-1 infected children.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Phase 3
  • Randomized, Open-Label
  • Treatment-Experienced
  • Highly Active Antiretroviral Therapy
  • HIV
  • Tenofovir DF
  • Pediatrics
04

Who can participate

Ages eligible
2 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  • Documented laboratory diagnosis of -1 infection
  • Plasma HIV-1 RNA \< 400 copies/mL
  • Currently on a stable stavudine or zidovudine -containing antiretroviral therapy regimen for at least 12 weeks
  • Naive to tenofovir DF

Key Inclusion Criteria for the First 96-Week Extension

  • Completed 48 weeks of treatment in Arm 1 or Arm 2 of the study
  • \<18 years of age (at the start of the extension)
  • Participants initially randomized to Arm 2 will be given the option to replace stavudine or zidovudine with tenofovir DF in the 96-week extension at the investigator's discretion, if the investigator determines that tenofovir DF is safe and beneficial for the participant.

Key Inclusion Criteria for the Second and Third 96-Week Extension and Fourth Open-Ended Extension

  • Completed of treatment with study drug in the first extension phase
  • \<18 years of age at the start of the extension. This inclusion criterion is not applicable in those regions where tenofovir DF is not commercially available for treatment of HIV-1 infection in adults.

Key Exclusion Criteria:

  • Participants receiving ongoing therapy with any of the following
  • Nephrotoxic agents
  • Systemic chemotherapeutic agents
  • Systemic
  • Interleukin 2 (IL 2) and other immunomodulating agents
  • agents
  • Pregnant or lactating participants
  • Evidence of a gastrointestinal malabsorption syndrome or chronic nausea or vomiting which may confer an inability to receive an orally administered medication
  • Current alcohol or substance abuse judged by the investigator to potentially interfere with participant compliance
  • other than cutaneous Kaposi's sarcoma (KS) or basal cell carcinoma.
  • Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic therapy within 15 days prior to screening
  • Prior history of significant renal disease (ie, nephrotic syndrome, renal dysgenesis, polycystic kidney disease, congenital nephrosis)
  • Prior history of significant bone disease (ie, osteomalacia, chronic osteomyelitis, osteogenesis imperfecta, osteochondroses, multiple bone fractures)

Note: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Tenofovir DF

    Drug: Tenofovir DF

  • Active comparator
    stavudine or zidovudine

    Drug: Zidovudine · Drug: Stavudine

Interventions

  • Tenofovir DF (oral powder or tablet): 300-mg tablets for participants \> 37 kg; 8-mg/kg oral powder (up to 300 mg) for participants ≤ 37 kg. During the extension phase, participants whose weight increases to \> 37 kg may be switched from the oral powder to the tenofovir DF tablet.

    Also known as: Viread®

  • Zidovudine as prescribed by the investigator prior to study entry (pediatric participants \< 30 kg: 1 mg/kg/dose given every 12 hours; pediatric participants ≥ 30 kg: 30 mg twice daily).

  • Stavudine as prescribed by the investigator prior to study entry (pediatric participants 6 weeks to 12 years of age: 160 mg/m\^2 every 8 hours; pediatric participants \> 12 years of age: 300 mg twice daily).

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48

    This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 48 weeks of exposure to randomized study drug.

    Time frame: 48 weeks

Secondary outcomes

  1. Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 400 Copies/mL, Snapshot)

    This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug. The percentage of participants achieving HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: 48 weeks

  2. Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 50 Copies/mL, Snapshot)

    This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug. The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: 48 weeks

  3. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 96

    This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 96 weeks of exposure to TDF.

    Time frame: 96 weeks

  4. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 144

    This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 144 weeks of exposure to TDF.

    Time frame: 144 weeks

  5. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 192 Weeks

    This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 192 weeks of exposure to TDF.

    Time frame: 192 weeks

  6. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 240 Weeks

    This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 240 weeks of exposure to TDF.

    Time frame: 240 weeks

  7. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 288 Weeks

    This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 288 weeks of exposure to TDF.

    Time frame: 288 weeks

  8. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 336 Weeks

    This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 336 weeks of exposure to TDF.

    Time frame: 336 weeks

  9. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 384 Weeks

    This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 384 weeks of exposure to TDF.

    Time frame: 384 weeks

  10. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 432 Weeks

    This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 432 weeks of exposure to TDF.

    Time frame: 432 weeks

  11. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 480 Weeks

    This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 480 weeks of exposure to TDF.

    Time frame: 480 weeks

  12. Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 528 Weeks

    This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 528 weeks of exposure to TDF.

    Time frame: 528 weeks

  13. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 48 Weeks

    This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 48 weeks of exposure to randomized study drug.

    Time frame: 48 weeks

  14. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 96 Weeks

    This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 96 weeks of exposure to TDF.

    Time frame: 96 weeks

  15. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 144 Weeks

    This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 144 weeks of exposure to TDF.

    Time frame: 144 weeks

  16. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 192 Weeks

    This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 192 weeks of exposure to TDF.

    Time frame: 192 weeks

  17. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 240 Weeks

    This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 240 weeks of exposure to TDF.

    Time frame: 240 weeks

  18. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 288 Weeks

    This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 288 weeks of exposure to TDF.

    Time frame: 288 weeks

  19. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 336 Weeks

    This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 336 weeks of exposure to TDF.

    Time frame: 336 weeks

  20. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 384 Weeks

    This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 384 weeks of exposure to TDF.

    Time frame: 384 weeks

  21. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 432 Weeks

    This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 432 weeks of exposure to TDF.

    Time frame: 432 weeks

  22. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 480 Weeks

    This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 480 weeks of exposure to TDF.

    Time frame: 480 weeks

  23. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 528 Weeks

    This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 528 weeks of exposure to TDF.

    Time frame: 528 weeks

  24. Change From Baseline in CD4 Percentage at 48 Weeks

    This is the change from baseline in CD4 percentage after 48 weeks of exposure to randomized study drug.

    Time frame: Baseline and 48 weeks

  25. Change From Baseline in CD4 Percentage at 96 Weeks

    This is the change from baseline in CD4 percentage after 96 weeks of exposure to TDF.

    Time frame: Baseline and 96 weeks

  26. Change From Baseline in CD4 Percentage at 144 Weeks

    This is the change from baseline in CD4 percentage after 144 weeks of exposure to TDF.

    Time frame: Baseline and 144 weeks

  27. Change From Baseline in CD4 Percentage at 192 Weeks

    This is the change from baseline in CD4 percentage after 192 weeks of exposure to TDF.

    Time frame: Baseline and 192 weeks

  28. Change From Baseline in CD4 Percentage at 240 Weeks

    This is the change from baseline in CD4 percentage after 240 weeks of exposure to TDF.

    Time frame: Baseline and 240 weeks

  29. Change From Baseline in CD4 Percentage at 288 Weeks

    This is the change from baseline in CD4 percentage after 288 weeks of exposure to TDF.

    Time frame: Baseline and 288 weeks

  30. Change From Baseline in CD4 Percentage at 336 Weeks

    This is the change from baseline in CD4 percentage after 336 weeks of exposure to TDF.

    Time frame: Baseline and 336 weeks

  31. Change From Baseline in CD4 Percentage at 384 Weeks

    This is the change from baseline in CD4 percentage after 384 weeks of exposure to TDF.

    Time frame: Baseline and 384 weeks

  32. Change From Baseline in CD4 Percentage at 432 Weeks

    This is the change from baseline in CD4 percentage after 432 weeks of exposure to TDF.

    Time frame: Baseline and 432 weeks

  33. Change From Baseline in CD4 Percentage at 480 Weeks

    This is the change from baseline in CD4 percentage after 480 weeks of exposure to TDF.

    Time frame: Baseline and 480 weeks

  34. Change From Baseline in CD4 Percentage at 528 Weeks

    This is the change from baseline in CD4 percentage after 528 weeks of exposure to TDF.

    Time frame: Baseline and 528 weeks

  35. Change From Baseline in CD4 Cell Count (Cells/mm^3) at 48 Weeks

    This is the change from baseline in CD4 cell count after 48 weeks of exposure to randomized study drug.

    Time frame: Baseline and 48 weeks

  36. Change From Baseline in CD4 Cell Count (Cells/mm^3) at 96 Weeks

    This is the change from baseline in CD4 cell count after 96 weeks of exposure to TDF.

    Time frame: Baseline and 96 weeks

  37. Change From Baseline in CD4 Cell Count (Cells/mm^3) at 144 Weeks

    This is the change from baseline in CD4 cell count after 144 weeks of exposure to TDF.

    Time frame: Baseline and 144 weeks

  38. Change From Baseline in CD4 Cell Count (Cells/mm^3) at 192 Weeks

    This is the change from baseline in CD4 cell count after 192 weeks of exposure to TDF.

    Time frame: Baseline and 192 weeks

  39. Change From Baseline in CD4 Cell Count (Cells/mm^3) at 240 Weeks

    This is the change from baseline in CD4 cell count after 240 weeks of exposure to TDF.

    Time frame: Baseline and 240 weeks

  40. Change From Baseline in CD4 Cell Count (Cells/mm^3) at 288 Weeks

    This is the change from baseline in CD4 cell count after 288 weeks of exposure to TDF.

    Time frame: Baseline and 288 weeks

  41. Change From Baseline in CD4 Cell Count (Cells/mm^3) at 336 Weeks

    This is the change from baseline in CD4 cell count after 336 weeks of exposure to TDF.

    Time frame: Baseline and 336 weeks

  42. Change From Baseline in CD4 Cell Count (Cells/mm^3) at 384 Weeks

    This is the change from baseline in CD4 cell count after 384 weeks of exposure to TDF.

    Time frame: Baseline and 384 weeks

  43. Change From Baseline in CD4 Cell Count (Cells/mm^3) at 432 Weeks

    This is the change from baseline in CD4 cell count after 432 weeks of exposure to TDF.

    Time frame: Baseline and 432 weeks

  44. Change From Baseline in CD4 Cell Count (Cells/mm^3) at 480 Weeks

    This is the change from baseline in CD4 cell count after 480 weeks of exposure to TDF.

    Time frame: Baseline and 480 weeks

  45. Change From Baseline in CD4 Cell Count (Cells/mm^3) at 528 Weeks

    This is the change from baseline in CD4 cell count after 528 weeks of exposure to TDF.

    Time frame: Baseline and 528 weeks

07

Results

Posted Mar 22, 2012

Participant flow

Participants were enrolled at study sites in the United States, Panama, and the United Kingdom. The first participant was screened on 28 December 2006. The last study visit occurred on 16 August 2017.

Randomized Phase (Baseline to Week 48)
Participant flow — Randomized Phase (Baseline to Week 48)
MilestoneTenofovir DFStavudine or Zidovudine
Started4849
Completed4448
Not completed41
Withdrew: Withdrew consent21
Withdrew: Safety, tolerability, or efficacy reason20
First Extension (Week 48 to Week 144)
Participant flow — First Extension (Week 48 to Week 144)
MilestoneTenofovir DFStavudine or Zidovudine
Started3841
Completed3540
Not completed31
Withdrew: Investigator's discretion20
Withdrew: Safety, tolerability, or efficacy reason10
Withdrew: Withdrew consent01
Second Extension (Week 144 to Week 240)
Participant flow — Second Extension (Week 144 to Week 240)
MilestoneTenofovir DFStavudine or Zidovudine
Started3440
Completed2737
Not completed73
Withdrew: Safety, tolerability, or efficacy reason43
Withdrew: Investigator's discretion30
Third Extension (Week 240 to Week 336)
Participant flow — Third Extension (Week 240 to Week 336)
MilestoneTenofovir DFStavudine or Zidovudine
Started2737
Completed2127
Not completed610
Withdrew: Safety, tolerability, or efficacy reason54
Withdrew: Lost to follow-up03
Withdrew: = 18 yr old & tdf approved in adults11
Withdrew: Investigator's discretion01
Withdrew: Withdrew consent01
Long-Term Extension (Week 336 and On)
Participant flow — Long-Term Extension (Week 336 and On)
MilestoneTenofovir DFStavudine or Zidovudine
Started1925
Completed98
Not completed1017
Withdrew: Rolled over to study gs-us-311-1269410
Withdrew: Safety, tolerability, or efficacy reason35
Withdrew: Withdrew consent21
Withdrew: Investigator's discretion11

Outcome measures

PrimaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48

This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 48 weeks of exposure to randomized study drug.

Time frame:
48 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48
percentage of participantsTenofovir DFStavudine or ZidovudineAll TDF
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 4883.3 (69.8 to 92.5)91.8 (80.4 to 97.7)85.4 (76.3 to 92.0)
Statistical analysis
  • Tenofovir DF vs Stavudine or Zidovudine · Normal approximation · Difference in percentages between groups: -8.5 · 95% CI -21.5 to 4.5Difference is for tenofovir DF minus stavudine or zidovudine (randomized phase)
SecondaryVirologic Success at 48 Weeks (HIV-1 RNA Cutoff at 400 Copies/mL, Snapshot)

This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug. The percentage of participants achieving HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
48 weeks
Reported as:
Number · percentage of participants
Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 400 Copies/mL, Snapshot)
percentage of participantsTenofovir DFStavudine or Zidovudine
Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 400 Copies/mL, Snapshot)88.689.6
Statistical analysis
  • Tenofovir DF vs Stavudine or Zidovudine · Difference in percentages between groups: -0.9 · 95% CI -13.7 to 11.8The difference between the two proportions and its CI were based on normal approximation methods.
SecondaryVirologic Success at 48 Weeks (HIV-1 RNA Cutoff at 50 Copies/mL, Snapshot)

This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug. The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
48 weeks
Reported as:
Number · percentage of participants
Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 50 Copies/mL, Snapshot)
percentage of participantsTenofovir DFStavudine or Zidovudine
Virologic Success at 48 Weeks (HIV-1 RNA Cutoff at 50 Copies/mL, Snapshot)75.081.3
SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 96

This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 96 weeks of exposure to TDF.

Time frame:
96 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 96
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 9681.685.483.5
SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 144

This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 144 weeks of exposure to TDF.

Time frame:
144 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 144
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 14473.787.580.8
SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at 192 Weeks

This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 192 weeks of exposure to TDF.

Time frame:
192 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 192 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 192 Weeks70.682.577.0
SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at 240 Weeks

This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 240 weeks of exposure to TDF.

Time frame:
240 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 240 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 240 Weeks70.675.773.2
SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at 288 Weeks

This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 288 weeks of exposure to TDF.

Time frame:
288 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 288 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 288 Weeks81.567.673.4
SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at 336 Weeks

This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 336 weeks of exposure to TDF.

Time frame:
336 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 336 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 336 Weeks90.9100.095.3
SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at 384 Weeks

This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 384 weeks of exposure to TDF.

Time frame:
384 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 384 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 384 Weeks100.0100.0100.0
SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at 432 Weeks

This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 432 weeks of exposure to TDF.

Time frame:
432 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 432 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 432 Weeks100.085.795.0
SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at 480 Weeks

This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 480 weeks of exposure to TDF.

Time frame:
480 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 480 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 480 Weeks88.9100.090.9
SecondaryPercentage of Participants With HIV-1 RNA < 400 Copies/mL at 528 Weeks

This is the percentage of participants with HIV-1 RNA \< 400 copies/mL after 528 weeks of exposure to TDF.

Time frame:
528 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 528 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at 528 Weeks100.0—100.0
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at 48 Weeks

This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 48 weeks of exposure to randomized study drug.

Time frame:
48 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 48 Weeks
percentage of participantsTenofovir DFStavudine or ZidovudineAll TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 48 Weeks70.885.768.5
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at 96 Weeks

This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 96 weeks of exposure to TDF.

Time frame:
96 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 96 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 96 Weeks76.368.372.2
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at 144 Weeks

This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 144 weeks of exposure to TDF.

Time frame:
144 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 144 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 144 Weeks63.275.069.2
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at 192 Weeks

This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 192 weeks of exposure to TDF.

Time frame:
192 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 192 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 192 Weeks67.675.071.6
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at 240 Weeks

This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 240 weeks of exposure to TDF.

Time frame:
240 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 240 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 240 Weeks70.673.071.8
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at 288 Weeks

This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 288 weeks of exposure to TDF.

Time frame:
288 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 288 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 288 Weeks81.562.270.3
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at 336 Weeks

This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 336 weeks of exposure to TDF.

Time frame:
336 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 336 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 336 Weeks86.490.588.4
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at 384 Weeks

This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 384 weeks of exposure to TDF.

Time frame:
384 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 384 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 384 Weeks88.2100.092.3
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at 432 Weeks

This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 432 weeks of exposure to TDF.

Time frame:
432 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 432 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 432 Weeks100.071.490.0
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at 480 Weeks

This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 480 weeks of exposure to TDF.

Time frame:
480 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 480 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 480 Weeks77.850.072.7
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at 528 Weeks

This is the percentage of participants with HIV-1 RNA \< 50 copies/mL after 528 weeks of exposure to TDF.

Time frame:
528 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 528 Weeks
percentage of participantsTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at 528 Weeks100.0—100.0
SecondaryChange From Baseline in CD4 Percentage at 48 Weeks

This is the change from baseline in CD4 percentage after 48 weeks of exposure to randomized study drug.

Time frame:
Baseline and 48 weeks
Reported as:
Mean · percentage
Change From Baseline in CD4 Percentage at 48 Weeks
percentageTenofovir DFStavudine or ZidovudineAll TDF
Change From Baseline in CD4 Percentage at 48 Weeks0.3 ± 4.491.1 ± 4.730.6 ± 3.85
SecondaryChange From Baseline in CD4 Percentage at 96 Weeks

This is the change from baseline in CD4 percentage after 96 weeks of exposure to TDF.

Time frame:
Baseline and 96 weeks
Reported as:
Mean · percentage
Change From Baseline in CD4 Percentage at 96 Weeks
percentageTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Percentage at 96 Weeks1.3 ± 4.08-0.1 ± 3.600.6 ± 3.88
SecondaryChange From Baseline in CD4 Percentage at 144 Weeks

This is the change from baseline in CD4 percentage after 144 weeks of exposure to TDF.

Time frame:
Baseline and 144 weeks
Reported as:
Mean · percentage
Change From Baseline in CD4 Percentage at 144 Weeks
percentageTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Percentage at 144 Weeks0.8 ± 5.61-0.1 ± 3.830.3 ± 4.73
SecondaryChange From Baseline in CD4 Percentage at 192 Weeks

This is the change from baseline in CD4 percentage after 192 weeks of exposure to TDF.

Time frame:
Baseline and 192 weeks
Reported as:
Mean · percentage
Change From Baseline in CD4 Percentage at 192 Weeks
percentageTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Percentage at 192 Weeks1.1 ± 5.570.6 ± 3.690.8 ± 4.58
SecondaryChange From Baseline in CD4 Percentage at 240 Weeks

This is the change from baseline in CD4 percentage after 240 weeks of exposure to TDF.

Time frame:
Baseline and 240 weeks
Reported as:
Mean · percentage
Change From Baseline in CD4 Percentage at 240 Weeks
percentageTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Percentage at 240 Weeks1.3 ± 5.98-0.9 ± 4.130.1 ± 5.16
SecondaryChange From Baseline in CD4 Percentage at 288 Weeks

This is the change from baseline in CD4 percentage after 288 weeks of exposure to TDF.

Time frame:
Baseline and 288 weeks
Reported as:
Mean · percentage
Change From Baseline in CD4 Percentage at 288 Weeks
percentageTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Percentage at 288 Weeks2.0 ± 6.300.5 ± 4.771.3 ± 5.58
SecondaryChange From Baseline in CD4 Percentage at 336 Weeks

This is the change from baseline in CD4 percentage after 336 weeks of exposure to TDF.

Time frame:
Baseline and 336 weeks
Reported as:
Mean · percentage
Change From Baseline in CD4 Percentage at 336 Weeks
percentageTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Percentage at 336 Weeks2.0 ± 7.190.8 ± 4.011.4 ± 5.82
SecondaryChange From Baseline in CD4 Percentage at 384 Weeks

This is the change from baseline in CD4 percentage after 384 weeks of exposure to TDF.

Time frame:
Baseline and 384 weeks
Reported as:
Mean · percentage
Change From Baseline in CD4 Percentage at 384 Weeks
percentageTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Percentage at 384 Weeks0.5 ± 7.801.6 ± 1.900.9 ± 6.37
SecondaryChange From Baseline in CD4 Percentage at 432 Weeks

This is the change from baseline in CD4 percentage after 432 weeks of exposure to TDF.

Time frame:
Baseline and 432 weeks
Reported as:
Mean · percentage
Change From Baseline in CD4 Percentage at 432 Weeks
percentageTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Percentage at 432 Weeks0.3 ± 6.412.9 ± 3.531.1 ± 5.66
SecondaryChange From Baseline in CD4 Percentage at 480 Weeks

This is the change from baseline in CD4 percentage after 480 weeks of exposure to TDF.

Time frame:
Baseline and 480 weeks
Reported as:
Mean · percentage
Change From Baseline in CD4 Percentage at 480 Weeks
percentageTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Percentage at 480 Weeks2.3 ± 7.155.0 ± 10.002.9 ± 7.51
SecondaryChange From Baseline in CD4 Percentage at 528 Weeks

This is the change from baseline in CD4 percentage after 528 weeks of exposure to TDF.

Time frame:
Baseline and 528 weeks
Reported as:
Mean · percentage
Change From Baseline in CD4 Percentage at 528 Weeks
percentageTenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Percentage at 528 Weeks4.5 ± 3.89—4.5 ± 3.89
SecondaryChange From Baseline in CD4 Cell Count (Cells/mm^3) at 48 Weeks

This is the change from baseline in CD4 cell count after 48 weeks of exposure to randomized study drug.

Time frame:
Baseline and 48 weeks
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 48 Weeks
cells/mm^3Tenofovir DFStavudine or ZidovudineAll TDF
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 48 Weeks-97 ± 416.4-11 ± 280.22 ± 385.9
SecondaryChange From Baseline in CD4 Cell Count (Cells/mm^3) at 96 Weeks

This is the change from baseline in CD4 cell count after 96 weeks of exposure to TDF.

Time frame:
Baseline and 96 weeks
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 96 Weeks
cells/mm^3Tenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 96 Weeks-77 ± 408.3-56 ± 305.6-67 ± 358.3
SecondaryChange From Baseline in CD4 Cell Count (Cells/mm^3) at 144 Weeks

This is the change from baseline in CD4 cell count after 144 weeks of exposure to TDF.

Time frame:
Baseline and 144 weeks
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 144 Weeks
cells/mm^3Tenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 144 Weeks-139 ± 438.2-146 ± 245.3-142 ± 345.9
SecondaryChange From Baseline in CD4 Cell Count (Cells/mm^3) at 192 Weeks

This is the change from baseline in CD4 cell count after 192 weeks of exposure to TDF.

Time frame:
Baseline and 192 weeks
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 192 Weeks
cells/mm^3Tenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 192 Weeks-304 ± 529.0-177 ± 288.5-233 ± 413.2
SecondaryChange From Baseline in CD4 Cell Count (Cells/mm^3) at 240 Weeks

This is the change from baseline in CD4 cell count after 240 weeks of exposure to TDF.

Time frame:
Baseline and 240 weeks
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 240 Weeks
cells/mm^3Tenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 240 Weeks-369 ± 529.9-296 ± 252.6-329 ± 401.7
SecondaryChange From Baseline in CD4 Cell Count (Cells/mm^3) at 288 Weeks

This is the change from baseline in CD4 cell count after 288 weeks of exposure to TDF.

Time frame:
Baseline and 288 weeks
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 288 Weeks
cells/mm^3Tenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 288 Weeks-346 ± 507.5-256 ± 292.5-302 ± 414.6
SecondaryChange From Baseline in CD4 Cell Count (Cells/mm^3) at 336 Weeks

This is the change from baseline in CD4 cell count after 336 weeks of exposure to TDF.

Time frame:
Baseline and 336 weeks
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 336 Weeks
cells/mm^3Tenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 336 Weeks-415 ± 569.4-283 ± 252.2-350 ± 443.8
SecondaryChange From Baseline in CD4 Cell Count (Cells/mm^3) at 384 Weeks

This is the change from baseline in CD4 cell count after 384 weeks of exposure to TDF.

Time frame:
Baseline and 384 weeks
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 384 Weeks
cells/mm^3Tenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 384 Weeks-620 ± 635.6-305 ± 238.2-512 ± 548.8
SecondaryChange From Baseline in CD4 Cell Count (Cells/mm^3) at 432 Weeks

This is the change from baseline in CD4 cell count after 432 weeks of exposure to TDF.

Time frame:
Baseline and 432 weeks
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 432 Weeks
cells/mm^3Tenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 432 Weeks-795 ± 559.2-302 ± 355.2-631 ± 545.7
SecondaryChange From Baseline in CD4 Cell Count (Cells/mm^3) at 480 Weeks

This is the change from baseline in CD4 cell count after 480 weeks of exposure to TDF.

Time frame:
Baseline and 480 weeks
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 480 Weeks
cells/mm^3Tenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 480 Weeks-923 ± 755.4-448 ± 469.9-813 ± 712.9
SecondaryChange From Baseline in CD4 Cell Count (Cells/mm^3) at 528 Weeks

This is the change from baseline in CD4 cell count after 528 weeks of exposure to TDF.

Time frame:
Baseline and 528 weeks
Reported as:
Mean · cells/mm^3
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 528 Weeks
cells/mm^3Tenofovir DF(Stavudine or Zidovudine)/TDFAll TDF
Change From Baseline in CD4 Cell Count (Cells/mm^3) at 528 Weeks-710 ± 447.0—-710 ± 447.0

Adverse events

Collected over Adverse events (AEs) were reported in the open-label randomized period (Weeks 0-48), and during the extension period when all participants received tenofovir DF.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tenofovir DF0/48 (0%)2/48 (4.2%)37/48 (77.1%)
Stavudine or Zidovudine0/49 (0%)2/49 (4.1%)35/49 (71.4%)
All TDF0/89 (0%)15/89 (16.9%)82/89 (92.1%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventTenofovir DFStavudine or ZidovudineAll TDF
PneumoniaInfections and infestations1/480/492/89
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/480/492/89
PharyngotonsillitisInfections and infestations1/480/491/89
LymphadenitisBlood and lymphatic system disorders0/481/490/89
Asthmatic crisisRespiratory, thoracic and mediastinal disorders0/481/490/89
Abdominal adhesionsGastrointestinal disorders0/480/491/89
DiarrhoeaGastrointestinal disorders0/480/491/89
AmoebiasisInfections and infestations0/480/491/89
AppendicitisInfections and infestations0/480/491/89
CellulitisInfections and infestations0/480/491/89
Most frequent other events
Showing 10 of 33
Most frequent other events
EventTenofovir DFStavudine or ZidovudineAll TDF
Viral upper respiratory tract infectionInfections and infestations17/4817/4957/89
Dental cariesGastrointestinal disorders1/481/4922/89
DiarrhoeaGastrointestinal disorders4/481/4920/89
CoughRespiratory, thoracic and mediastinal disorders6/487/4920/89
GastroenteritisInfections and infestations3/484/4918/89
Otitis mediaInfections and infestations7/484/4916/89
PharyngitisInfections and infestations1/480/4916/89
ArthralgiaMusculoskeletal and connective tissue disorders0/481/4915/89
PyrexiaGeneral disorders1/483/4914/89
PharyngotonsillitisInfections and infestations1/481/4914/89

Baseline characteristics

Randomized and Treated Set: participants who were randomized and received at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)Tenofovir DFStavudine or ZidovudineTotal
Mean7 ± 3.37 ± 2.67 ± 3.0
Sex: Female, Male
Sex: Female, Male(Participants)Tenofovir DFStavudine or ZidovudineTotal
Female272047
Male212950
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tenofovir DFStavudine or ZidovudineTotal
Hispanic or Latino354277
Not Hispanic or Latino13720
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tenofovir DFStavudine or ZidovudineTotal
American Indian or Alaska Native202
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American13619
White369
Mestizo283765
Native Indian (Kuna)101
Region of Enrollment
Region of Enrollment(Participants)Tenofovir DFStavudine or ZidovudineTotal
United States13922
Panama333972
United Kingdom213
Height
Height(cm)Tenofovir DFStavudine or ZidovudineTotal
Mean118 ± 19.8119 ± 16.7119 ± 18.2
Body Mass Index
Body Mass Index(kg/m^2)Tenofovir DFStavudine or ZidovudineTotal
Mean17.59 ± 3.68016.59 ± 1.76217.08 ± 2.905
Weight
Weight(kilograms)Tenofovir DFStavudine or ZidovudineTotal
Mean25.9 ± 12.0324.1 ± 7.7725.0 ± 10.09

3 further baseline measures are reported on the registry.

08

Study locations

9 sites
  • Jeffrey Goodman Special Care Clinic
    Los Angeles, California 90027, United States
  • University California Los Angeles, School of Medicine, Pediatric, Infectious Diseases
    Los Angeles, California 90095, United States
  • Children's Diagnostic and Treatment Center, Inc
    Fort Lauderdale, Florida 33316, United States
  • University of Florida, Jacksonville
    Jacksonville, Florida 32209, United States
  • St. Christopher's Hospital for Children
    Philadelphia, Pennsylvania 19134, United States
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
  • Hospital del Nino
    Panama City, Panama
  • Great Ormond Street Hospital
    London, United Kingdom
  • Imperial College London, Paediatrics Infectious Diseases
    London, United Kingdom
09

References and documents

Publications

  • Saez-Llorens X, Castano E, Rathore M, Church J, Deville J, Gaur A, Estripeaut D, White K, Arterburn S, Enejosa JV, Cheng AK, Chuck SL, Rhee MS. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression. Pediatr Infect Dis J. 2015 Apr;34(4):376-82. doi: 10.1097/INF.0000000000000289. PubMed 25760565 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2006 to primary completion in Apr 2009, 27 months.

Results were first posted in Mar 2012, 2 years 11 months after primary completion. A results delay was requested in Jun 2011.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 27 months is above that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2007
First posted
Sep 14, 2007
StartActual
Dec 28, 2006
Primary completionActual
Apr 6, 2009
CompletionActual
Aug 16, 2017
Results delay requested
Jun 8, 2011
Results first posted
Mar 22, 2012
Last update
Mar 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00528957
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Sep 14, 2007
Start date
Dec 28, 2006
Primary completion
Apr 6, 2009
Completion
Aug 16, 2017
Results posted
Mar 22, 2012
Last update
Mar 14, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion